Pharmacological induction of ferritin prevents osteoblastic transformation of smooth muscle cells

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 2, 2016, Pages 217-230

  Becs, Gergely ^a   Zarjou, Abolfazl ^b   Agarwal, Anupam ^b   Kovács, Katalin Éva ^a   Becs, Ádám ^a   Nyitrai, Mónika ^a   Balogh, Eniko ^a   Bányai, Emese ^a   Eaton, John W ^c   Arosio, Paolo ^d   Poli, Maura ^d   Jeney, Viktória ^a,e   Balla, József ^a,e   Balla, György ^a,e  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d UNIVERSITY OF BRESCIA   (Italy)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Ferritin; Ferroxidase activity; Vascular calcification; Vitamin D3; glycerophosphate

Indexed keywords

ALKALINE PHOSPHATASE; APOFERRITIN; CALCITRIOL; CALCIUM; CERULOPLASMIN; COLECALCIFEROL; FERRITIN; GLYCEROL 2 PHOSPHATE; HOLOFERRITIN; LEVAMISOLE; MESSENGER RNA; OSTEOCALCIN; PARICALCITOL; PHOSPHATE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; 1,2-DITHIOL-3-THIONE; BETA-GLYCEROPHOSPHORIC ACID; ERGOCALCIFEROL; GLYCEROPHOSPHATE; THIOKETONE; THIOPHENE DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; BLOOD VESSEL CALCIFICATION; CELL TRANSFORMATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; END STAGE RENAL DISEASE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIALYSIS; HUMAN; HUMAN CELL; HYPERPARATHYROIDISM; IMMUNOFLUORESCENCE TEST; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SMOOTH MUSCLE FIBER; WESTERN BLOTTING; AORTA; CELL CULTURE; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ALKALINE PHOSPHATASE; AORTA; CALCITRIOL; CALCIUM; CELLS, CULTURED; CHOLECALCIFEROL; ERGOCALCIFEROLS; FERRITINS; GLYCEROPHOSPHATES; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOBLASTS; OSTEOCALCIN; PHOSPHATES; THIONES; THIOPHENES; VASCULAR CALCIFICATION;

EID: 84955734750     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12682     Document Type: Article

References (45)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32: S112-9.
2. Alani H, Tamimi A, Tamimi N. Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs. World J Nephrol. 2014; 3: 156-68.
3. Ardhanari S, Alpert MA, Aggarwal K. Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention. Adv Perit Dial. 2014; 30: 40-53.
4. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009; 20: 1453-64.
5. McCullough PA, Agrawal V, Danielewicz E, et al. Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3: 1585-98.
6. Beadenkopf WG, Daoud AS, Love BM. Calcification in the coronary arteries and its relationship to arteriosclerosis and myocardial infarction. Am J Roentgenol Radium Ther Nucl Med. 1964; 92: 865-71.
7. Giachelli CM, Steitz S, Jono S. Potential roles of bone matrix proteins in vascular calcification. Clin Calcium. 1999; 9: 20-7.
8. Lomashvili KA, Garg P, Narisawa S, et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int. 2008; 73: 1024-30.
9. Giachelli CM. Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res. 2005; 8: 229-31.
10. Giachelli CM, Jono S, Shioi A, et al. Vascular calcification and inorganic phosphate. Am J Kidney Dis. 2001; 38: S34-7.
11. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol. 2003; 14: S300-4.
12. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87: E10-7.
13. Shioi A, Nishizawa Y, Jono S, et al. Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995; 15: 2003-9.
14. Cardus A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res. 2007; 22: 860-6.
15. Henley C, Colloton M, Cattley RC, et al. 1, 25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant. 2005; 20: 1370-7.
16. Zarjou A, Jeney V, Arosio P, et al. Ferritin prevents calcification and osteoblastic differentiation of vascular smooth muscle cells. J Am Soc Nephrol. 2009; 20: 1254-63.
17. Cozzi A, Corsi B, Levi S, et al. Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in vivo role of ferritin ferroxidase activity. J Biol Chem. 2000; 275: 25122-9.
18. Wittwer I. Iron deficiency anaemia in chronic kidney disease. J Ren Care. 2013; 39: 182-8.
19. Huang ML, Austin CJ, Sari MA, et al. Hepcidin bound to alpha2-macroglobulin reduces ferroportin-1 expression and enhances its activity at reducing serum iron levels. J Biol Chem. 2013; 288: 25450-65.
20. Arosio P, Levi S. Ferritin, iron homeostasis, and oxidative damage. Free Radic Biol Med. 2002; 33: 457-63.
21. Kensler TW, Groopman JD, Sutter TR, et al. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem Res Toxicol. 1999; 12: 113-26.
22. Pietsch EC, Chan JY, Torti FM, et al. Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem. 2003; 278: 2361-9.
23. Broxmeyer HE, Cooper S, Levi S, et al. Mutated recombinant human heavy-chain ferritins and myelosuppression in vitro and in vivo: a link between ferritin ferroxidase activity and biological function. Proc Natl Acad Sci USA. 1991; 88: 770-4.
24. El-Abbadi MM, Pai AS, Leaf EM, et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009; 75: 1297-307.
25. Lau WL, Leaf EM, Hu MC, et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int. 2012; 82: 1261-70.
26. Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev. 2013; 9: 331-9.
27. Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol. 2014; 3: 99-104.
28. Kumar S, Bogle R, Banerjee D. Why do young people with chronic kidney disease die early? World J Nephrol. 2014; 3: 143-55.
29. Block GA. Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol. 2000; 54: 318-24.
30. Milliner DS, Zinsmeister AR, Lieberman E, et al. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int. 1990; 38: 931-6.
31. Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol. 2013; 38: 136-48.
32. Burke SK. Phosphate is a uremic toxin. J Ren Nutr. 2008; 18: 27-32.
33. Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013; 24: 179-89.
34. Ueno Y, Shinki T, Nagai Y, et al. In vivo administration of 1, 25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem. 2003; 90: 267-77.
35. Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta. 2009; 1790: 589-99.
36. Finazzi D, Arosio P. Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. Arch Toxicol. 2014; 88: 1787-802.
37. Alkhateeb AA, Connor JR. Nuclear ferritin: a new role for ferritin in cell biology. Biochim Biophys Acta. 2010; 1800: 793-7.
38. Coffman LG, Parsonage D, D'Agostino R Jr, et al. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci USA. 2009; 106: 570-5.
39. Zarjou A, Bolisetty S, Joseph R, et al. Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. J Clin Invest. 2013; 123: 4423-34.
40. Zarjou A, Jeney V, Arosio P, et al. Ferritin ferroxidase activity: a potent inhibitor of osteogenesis. J Bone Miner Res. 2010; 25: 164-72.
41. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem. 1992; 267: 18148-53.
42. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997; 89: 755-64.
43. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985; 28: 1-5.
44. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306: 2090-3.
45. Singh B, Arora S, Agrawal P, et al. Hepcidin: a novel peptide hormone regulating iron metabolism. Clin Chim Acta. 2011; 412: 823-30.